During the past decade, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center conducted 114 clinical trials. In the 10-year time frame, 114 clinical trials started and 55 clinical trials were completed, i.e. on average, 48.2% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 30 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center" #1 sponsor was "Children's Oncology Group" with 26 trials, followed by "National Cancer Institute (NCI)" with 19 trials sponsored, "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center" with 17 trials sponsored, "Gilead Sciences" with 13 trials sponsored and "Pfizer" with 13 trials sponsored. Other sponsors include 87 different institutions and companies that sponsored additional 59 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center" #1 collaborator was "National Cancer Institute (NCI)" with 27 trials as a collaborator, "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center" with 11 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 8 trials as a collaborator, "University of Washington" with 5 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 4 trials as a collaborator. Other collaborators include 81 different institutions and companies that were collaborators in the rest 74 trials.

According to Clinical.Site data, the most researched conditions in "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center" are "Pulmonary Disease, Chronic Obstructive" (8 trials), "HIV-1 Infection" (5 trials), "Male Contraception" (5 trials), "Malignant Solid Neoplasm" (5 trials) and "Systemic Lupus Erythematosus" (5 trials). Many other conditions were trialed in "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center" in a lesser frequency.

Most popular intervention types in "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center" are "Drug" (130 trials), "Other" (50 trials), "Biological" (20 trials), "Procedure" (17 trials) and "Radiation" (16 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (39 trials), "Laboratory Biomarker Analysis" (25 trials), "Cyclophosphamide" (17 trials), "Vincristine Sulfate" (16 trials) and "Cytarabine" (13 trials). Other intervention names were less common.

The vast majority of trials in "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center" are 157 trials for "All" genders, 16 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are 78 active trials in "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center". 1 are not yet recruiting, 37 are recruiting, 38 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 78 completed trials in Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, 2 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, 16 "Phase 1" clinical trials were conducted, 56 "Phase 2" clinical trials and 69 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 12 trials that are defined as “Not Applicable".